Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HPV E6 is a small, zinc-binding oncoprotein expressed by high-risk human papillomaviruses. It promotes the proteasome-dependent degradation of the tumor suppressor protein p53, inhibits apoptosis, and activates telomerase, contributing to cellular transformation and oncogenesis. It interacts with various host cell proteins, including E6AP, Bak/Bax, PDZ domain proteins, and NHERF1, affecting epithelial organization, polarity, differentiation, and immune evasion. Its activity is implicated in cervical cancer and other HPV-associated malignancies, making it a major focus for therapeutic intervention.
Not applicable; E6 is a viral protein targeted by therapeutics, not a drug itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus E6.